My watch list

Etretinate


Etretinate
Systematic (IUPAC) name
ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate
Identifiers
CAS number	54350-48-0
ATC code	D05BB01
PubChem	3312
DrugBank	APRD00966
Chemical data
Formula	C₂₃H₃₀O₃
Mol. mass	354.483 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Oral

Etretinate (trade name Tegison®) is a medication used to treat severe psoriasis. It was removed from the United States market in 1998 and the Canadian market in 1996, due to the high risk of birth defects.

Additional recommended knowledge

Daily Sensitivity Test

How to quickly check pipettes?

Daily Visual Balance Check

Precautions

Etretinate is a teratogen, and may cause birth defects long after use. Therefore, etretinate should only be used if one is never to get pregnant.
Etretinate should be avoided in children, as it may interfere with growth of bone.

Side effects

Hepatitis
Pseudotumor cerebri

v • d • e Antipsoriatics (D05)
Topical: tars	Tar
Topical: antracens	Dithranol
Topical: psoralens	Trioxysalen - Methoxsalen
Topical: other	Fumaric acid - Calcipotriol - Calcitriol - Tacalcitol - Tazarotene
Systemic: psoralens	Trioxysalen - Methoxsalen - Bergapten
Systemic: retinoids	Etretinate - Acitretin